Business
PRP Regulatory Progress – Canada
Genus PLC has announced a significant regulatory milestone as Canada has approved the use of its PRRS Resistant Pig (PRP) gene edit, a crucial step towards commercialisation in North America. This development follows extensive collaboration with Canadian regulatory bodies and addresses the substantial economic impact of PRRS, which a 2024 study estimated costs the U.S. $1.2 billion annually and increases antibiotic usage by over 200%. Genus is actively pursuing further approvals in key export markets like Mexico and Japan, as well as engaging with regulators in China. Disclaimer*
About this update from Genus Plc
[{"type":"text","content":"\n\n23 January 2026\nGenus plc (\"Genus\" or the \"Group\")\nPRP Regulatory Progress - Canada\nThis announcement contains inside information\nGenus (LSE: GNS), a leading global animal genetics company, announces the following update in relation to its innovative PRRS1 Resistant Pig (\"PRP\") programme. \nGenus is pleased to announce that Canada has approved use of the PRP gene edit. This approval follows years of close collaboration with multiple Canadian regulatory agencies and represents another important step towards PRP commercialisation in North America. Genus believes successful commercialisation of PRP in North America requires further approvals in key North American export markets, particularly Mexico and Japan. The Group continues to make progress with regulators in these jurisdictions as well as with other international regulators, including China.\nPRRS is one of the most devastating global pig diseases and causes suffering and premature death for pigs. A 2024 study from Iowa State University2 estimated the cost of PRRS to be $1.2 billion per annum in the U.S. alone and a separate study indicated that PRRS increased antibiotic usage by more than 200%3.\nFor further information please contact:\nGenus plc Tel: +44 125 634 5970\nJorgen Kokke, Chief Executive Officer\nAndy Russell, Chief Financial Officer\nAnand Date, Investor Relations & Sustainability Director\nBurson Buchanan Tel: +44 207 466 5000\nCharles Ryland; Mark Court; Toto Berger; Jamie Hooper\nThe information contained within this announcement is deemed by Genus to constitute inside information as stipulated under the Market Abuse Regulation (EU) no. 596/2014 (as incorporated into UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\"). On the publication of this announcement via a regulatory information service, this inside information is now considered to be in the public domain. The person responsible for arranging the release of this announcement is Lucie Grant, Group General Counsel and Company Secretary.\nAbout Genus\nGenus is a world-leading animal genetics company. Genus creates advances in an...